Physician profile
Terri B Cates
NPI 1326017278
$1,352.92
in general payments reported to CMS, 2019-2025
28 companies · $125 in 2025
The $125 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $165 · 2021: $20.61 · 2022: $134 · 2023: $244 · 2024: $362 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $158.77 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $112.87 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Pfizer INC. | $96.42 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $86.16 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $83.22 | 2019-2023 | Farxiga, Breztri |
| Cranial Technologies, INC | $82.10 | 2019-2025 | Doc Band |
| Tris Pharma INC | $61.95 | 2019-2020 | |
| Abbvie INC. | $56.48 | 2023-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $55.92 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.37 | 2019-2020 | |
| Exact Sciences Corporation | $51.64 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $50.81 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi Pasteur INC. | $50.56 | 2021-2023 | |
| Corium, LLC | $38.00 | 2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $36.68 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29.56 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.91 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.63 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $26.64 | 2022 | |
| Grifols USA, LLC | $25.38 | 2025 | Prolastin-C Liquid |
| Abbott Laboratories | $24.28 | 2022 | |
| Corcept Therapeutics | $24.18 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $17.66 | 2024 | Trintellix |
| Glaxosmithkline, LLC. | $16.97 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.30 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $16.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.13 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $11.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Cates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.